Meaning-Centered Counseling for Chinese Patients Who Are Being Treated for Advanced Cancer
NCT ID: NCT02112188
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
84 participants
OBSERVATIONAL
2014-04-30
2027-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Psychotherapy Intervention for Latinos With Advanced Cancer
NCT04015609
Psychotherapy Intervention for Latinos With Adv Cancer
NCT04537936
Randomized Controlled Trial of Group Psychotherapy Interventions for Cancer Patients
NCT00494910
A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
NCT07225309
Resilience in East Asian Immigrants for Advance Care Planning Discussions
NCT06035549
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase 3: Proof-of-concept" single-arm pilot trial of IMCP-Ch This phase will feature an open feasibility study using a pretest vs. posttest design, with the intervention to be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or by an English-speaking therapist in English (for bilingual Chinese and English-speaking patients who prefer English) or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference
Added a new phase (Phase 4), to examine the effects of using remote interpreting modalities to deliver IMCP-CH to Mandarin-speaking patients with advanced cancer; and (2) to add a minimum distress level for eligibility in order to align trial eligibility criteria with those employed in prior MCP trials, which used a DistressThermometer (DT) cutoff of \>4 to identify patients with clinically significant distress (participants who do not meet this criteria will be enrolled in Phase 3). Phase 4 will employ a three-arm pilot randomized controlled trial (RCT) design to test the feasibility and acceptability of using (1) Remote Consecutive Medical Interpretation (RCMI), (2) Remote Simultaneous Medical Interpretation (RSMI) and (3) bilingual provider (control/gold standard) in delivering IMCP-Ch.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chinese patients with advanced cancer
IMCP intervention to be culturally \& linguistically tailored for Chinese cancer patients. This study will be carried out in 3 phases: 1) formative research \& 2) adaptation. For this application we will continue the formative research (phase 1) by conducting 20 to 30 indepth interviews with Chinese immigrants with advanced cancer to inform the adaptation of the intervention. Results of the patient in-depth interviews will inform how to adapt the IMCP process \& session themes to reflect the needs of the community. In the adaptation phase (phase 2) the Breitbart IMCP research team (including Drs. Breitbart, Lichtenthal, \& Applebaum), Drs. Leng, Gany, \& Ms. Huang will discuss a priori adaptations to the intervention. Potential changes to the process \& content will be discussed. Adaptations will be incorporated in a modified IMCP-Ch treatment manual, therapist checklist/outline \& Treatment Integrity Coding Manual. PHASE 3, 4 Conduct feasibility study of IMCP-Ch for Chinese cancer patients.
In-depth Patient Interviews
Adaptation of IMCP for Chinese Immigrant Cancer Patients
Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)
The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
In-depth Patient Interviews
Adaptation of IMCP for Chinese Immigrant Cancer Patients
Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)
The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-US born;
* Of Chinese descent;
* Age 21 years through 80 years;
* Language spoken: Mandarin and/or English
* Diagnosis of Stage IV cancer (any type).
Phase 3:
* Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred.
* Age 18 or older
* Of Chinese descent
* Mandarin-speaking
* Have an estimated life expectancy of at least 6 months (per self-report or on the MSKCC EMR)
* Resides in New York State or New Jersey
Phase 4:
* Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred.
* Age 18 or older
* Of Chinese descent
* Mandarin-speaking
* Have an estimated life expectancy of at least 6 months (per referring physician assessment or on the MSKCC EMR)
* Resides in New York State or New Jersey
Exclusion Criteria
* Presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection. The Chinese version of the Mini Mental State Examination (MMSE) (46) will be used as a cognitive screening tool. Patients with MMSE scores below 20 will be excluded. For English speaking patients we will use the English version of the MMSE.
* Has a household member who has already participated (or agreed to participate).
Phase 3:
* Previous participation in Phases 1 or 2 of the study
* Unable/unwilling to use or no access to a telehealth platform (i.e., telephone or videoconference)
* For participants who express interest in RSMI, unable/unwilling to use Zoom videoconferencing platform
* Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments
* Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation
* Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires
* Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR)
* Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report)
Phase 4:
* Previous participation in Phases 1, 2, or 3 of the study
* Unable/unwilling to use or no access to the Zoom videoconferencing platform (required for RSMI)
* Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments
* Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation
* Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires
* Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR)
* Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report)
21 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queens Cancer Center of Queens Hospital
OTHER
Charles B. Wang Community Health Center (CBWCHC)
UNKNOWN
American Cancer Society - Asian Initiatives
OTHER
New York Coalition for Asian American Mental Health (NYCAAMH)
UNKNOWN
New York Hospital Queens
OTHER
Chinese Christian Herald Crusades (CCHC)
OTHER
Cheung and Kan Medical Group, PLLC
UNKNOWN
The City College of New York
OTHER
MediSys Health Network
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Florence Lui, PhD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States
City College of New York (Data Collection AND Data Analysis)
New York, New York, United States
MSK at Ralph Lauren (Limited Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-076
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.